This article is more than 5 years old. Information may no longer be current.
How to approach CyPass cases after recall
Click Here to Manage Email Alerts
SAN DIEGO — Trimming or removing the CyPass micro-stent is recommended for patients who are experiencing endothelial cell loss, while regular monitoring is recommended for CyPass patients still doing well, according to a speaker here.
The CyPass micro-stent was recalled by Alcon in October 2018 due to the potential to cause endothelial cell loss, as found in the COMPASS-XT study.
Patients with the CyPass are encouraged to make an appointment with their eye care professional as soon as possible, and those eye care providers should be monitoring patients regularly, Steven D. Vold, MD, said at Glaucoma Subspecialty Day at the American Society of Cataract and Refractive Surgery annual meeting.
“The key thing I think is being very vigilant,” he said.
The FDA recommends periodic assessment with specular microscopy. Vold recommended sending letters to all patients who received the CyPass and evaluating those patients at least every 6 months.
In cases of progressive endothelial cell loss, trimming or removing the CyPass is necessary, but it is something that should be done with care, he said.
“This is not something you want to take lightly,” Vold said. – by Rebecca L. Forand
Reference: Vold S. CyPass micro-stent removal/trimming. Presented at: American Society of Cataract and Refractive Surgery annual meeting; May 3-7, 2019; San Diego.
Disclosure: Vold reports he is founder and CEO of Vold Vision, receives research support or consults for Alcon, Allergan, Aerie Pharmaceuticals, Allergan, Bausch + Lomb, Glaukos, Carl Zeiss Meditec, iStar Medical, Ivantis, Lumenis, O3 Optix, Ocular Therapeutix, ReVision Optics, RxSight, Santen, Sight Sciences and Volk Optical. He is a stockholder or shareholder for Alphaeon, Iantech, TrueVision Systems and O3 Optix, and is a speaker for Neomedix and Allergan.